A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients

被引：0
|
作者：
Lee, Valerie
Wang, Judy
El Khoueiry, Anthony
Verheul, Henk
Gootjes, Elske
Sharma, Anup
Kerner, Zachary
Jones, Peter
Baylin, Stephen
Lilly, Ellen
Ahuja, Nita
Brown, Thomas
Azad, Nilofer
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-CT017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT017
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Irinotecan (Iri) and buparlisib (B) in previously treated patients (pts) with metastatic colorectal cancer (mCRC).
    Baranda, Joaquina Celebre
    Reed, Greg
    Williamson, Stephen K.
    Perez, Raymond P.
    Stoltz, Maxine L.
    Mackay, Chris
    Madan, Rashna
    Pessetto, Ziyan Y.
    Godwin, Andrew K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)
    Lee, V.
    Zahurak, M.
    Cercek, A.
    Verheul, H.
    Lenz, H.
    Jones, P.
    Baylin, S.
    Parkinson, R.
    Rami, V.
    Lilly, E.
    Miles, T.
    Brown, T.
    Ahuja, N.
    El Khoueiry, A.
    Azad, N.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S12 - S12
  • [3] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Baron, A. D.
    O'Bryant, C. L.
    Choi, Y.
    Ashkenazi, A.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] A PHASE I TRIAL OF IRINOTECAN (IRI) AND BKM120 IN PREVIOUSLY TREATED PATIENTS (PTS) WITH METASTIC COLORECTAL CANCER (MCRC)
    Baranda, J. C.
    Reed, G.
    Williamson, S.
    Dickman, E.
    Stoltz, M.
    Madan, R.
    Wright, L.
    Bhalla, K.
    Godwin, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 223 - 223
  • [5] A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan
    Lee, Valerie
    Wang, Judy
    Zahurak, Marianna
    Gootjes, Elske
    Verheul, Henk M.
    Parkinson, Rose
    Kerner, Zachary
    Sharma, Anup
    Rosner, Gary
    De Jesus-Acosta, Ana
    Laheru, Daniel
    Le, Dung T.
    Oganesian, Aram
    Lilly, Ellen
    Brown, Thomas
    Jones, Peter
    Baylin, Stephen
    Ahuja, Nita
    Azad, Nilofer
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6160 - 6167
  • [6] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI with or without bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC).
    Baron, A. D.
    O'Bryant, C. L.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [7] Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) in previously treated metastatic colorectal cancer (mCRC).
    Meyerhardt, J. A.
    Schrag, D.
    Kulke, M.
    Enzinger, P. C.
    Chan, J. A.
    Blaszkowsky, L. S.
    Goldstein, M.
    Allen, B.
    Regan, E.
    Abrams, T. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer
    Kemeny, N
    Tong, W
    Gonen, M
    Stockman, J
    Di Lauro, C
    Teitcher, J
    White, P
    Price, C
    Saltz, L
    Sharma, S
    Graham, MA
    ANNALS OF ONCOLOGY, 2002, 13 (09) : 1490 - 1496
  • [9] A phase I study of investigational agent SGI-110 combined with irinotecan in previously treated metastatic colorectal cancer patients.
    Wang, Judy Sing-Zan
    Gootjes, Elske C.
    Uram, Jennifer N.
    Zahurak, Marianna
    El-Khoueiry, Anthony B.
    Verheul, Henk M. W.
    Ahuja, Nita
    Azad, Nilofer Saba
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [10] PHASE II STUDY OF S-1 COMBINED WITH IRINOTECAN AND OXALIPLATIN (TIROX) IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Hong, Y. S.
    Kim, S. Y.
    Park, J. W.
    Lim, S.
    Choi, H. S.
    Jeong, S. Y.
    Kim, D. Y.
    Hong, C. W.
    Sohn, D. K.
    Jung, K. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 136
12345